Volunteers are to be recruited from today for a world-first study that will mix and match Covid-19 vaccines.
The trial on more than 800 people over the age of 50 will compare the effect of giving a dose of the AstraZeneca/Oxford vaccine followed a few weeks later by the Pfizer/BioNTech jab or vice versa.
The interval between the doses will be either four or 12 weeks to test whether giving the immune response a longer time to mature can improve the result.
Initial results should be available by the summer.
Professor Matthew Snape, a vaccinologist at Oxford University and part of the Oxford vaccine team, said the ability to use different jabs would guard against any supply problems.
He said: "If we do show that these vaccines can be used interchangeably in the same schedule this will greatly increase the flexibility of vaccine delivery, and could provide clues as to how to increase the breadth of protection against new virus strains."
The study, run by the National Immunisation Schedule Evaluation Consortium (NISEC), will be run at eight hospital centres around England. Volunteers will be recruited over the next two to three weeks through the Covid-19 Vaccine Research Registry.
They will have regular blood tests to assess their levels of antibodies and T-cells, which help to clear infections and act as an immune memory.
Further vaccines could also be added to the mix once they are approved by the medical regulator.
Minister for Covid-19 Vaccine Deployment Nadhim Zahawi said: "This is a hugely important clinical trial that will provide us with more vital evidence on the safety of these vaccines when used in different ways."
There are no current plans to alter the current vaccine schedule, which has a gap of up to 12 weeks between two doses of the same jab.
Dr Peter English, a consultant in communicable disease control at Public Health England, said: "Many vaccines work better if a different vaccine is used for boosting - an approach described as heterologous boosting.
"Examples include hepatitis B, where some people respond poorly to vaccination but better if a heterologous booster is given."
Latest Stories
-
FIFA Club World Cup 2025: Sundowns, Esperance join Al Ahly and Wydad as CAF representatives
3 hours -
CAFCL: Al Ahly set up historic final with ES Tunis
3 hours -
We didn’t sneak out 10 BVDs; they were auctioned as obsolete equipment – EC
7 hours -
King Charles to resume public duties after progress in cancer treatment
8 hours -
Arda Guler scores on first start in La Liga as Madrid beat Real Sociedad
8 hours -
Fatawu Issahaku’s Leicester City secures Premier League promotion after Leeds defeat
8 hours -
Anticipation builds as Junior Speller hosts nationwide auditions
9 hours -
Etse Sikanku: The driver’s mate conundrum
9 hours -
IMF Deputy Chief worried large chunk of Eurobonds is used to service debt
10 hours -
Otumfuo Osei Tutu II celebrates 25 years of peaceful rule on golden stool
10 hours -
We have enough funds to pay accruing benefits; we’ve never missed pension payments since 1991 – SSNIT
10 hours -
Let’s embrace shared vision and propel National Banking College – First Deputy Governor
11 hours -
Liverpool agree compensation deal with Feyenoord for Slot
11 hours -
Ejisu by-election: There’s no evidence of NPP engaging in vote-buying – Ahiagbah
11 hours -
Ejisu by-election: Independent ex-NPP MP’s campaign team warns party against dubious tactics
11 hours